XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
General - Schedule of Error Corrections and Prior Period Adjustments (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Balance Sheet for June 30, 2022 (unaudited)              
Additional paid-in capital $ 473,355       $ 473,355   $ 451,608
Accumulated deficit (473,686)       (473,686)   $ (457,484)
Consolidated Statement of Operations and Comprehensive Loss for the three months ended June 30, 2022 (unaudited)              
Research and development expenses 3,555   $ 5,606   8,131 $ 10,087  
Selling, general and administrative expenses 4,787   4,497   8,952 8,699  
Total operating expenses 8,342   10,103   17,083 18,786  
Operating loss (7,997)   (9,486)   (16,322) (17,826)  
Net loss (7,202) $ (9,000) (10,159) $ (9,000) (16,202) (19,159)  
Total other comprehensive loss $ (7,202)   $ (10,190)   $ (16,183) $ (19,188)  
Basic loss per common share (in dollars per share) $ (0.58)   $ (1.24)   $ (1.35) $ (2.34)  
Diluted loss per common share (in dollars per share) $ (0.58)   $ (1.24)   $ (1.35) $ (2.34)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended June 30, 2022 (unaudited)              
Compensation expense for issuance of stock options $ 1,661 1,661 $ 2,119 2,271      
Net loss (7,202) (9,000) (10,159) (9,000) $ (16,202) $ (19,159)  
Consolidated Statement of Cash Flows for the six months ended June 30, 2022 (unaudited)              
Net loss $ (7,202) $ (9,000) (10,159) $ (9,000) (16,202) (19,159)  
Stock option compensation expense         $ 3,322 4,390  
As previously reported              
Balance Sheet for June 30, 2022 (unaudited)              
Additional paid-in capital     435,922     435,922  
Accumulated deficit     (438,836)     (438,836)  
Consolidated Statement of Operations and Comprehensive Loss for the three months ended June 30, 2022 (unaudited)              
Research and development expenses     5,456     9,696  
Selling, general and administrative expenses     4,145     7,791  
Total operating expenses     9,601     17,487  
Operating loss     (8,984)     (16,527)  
Net loss     (9,657)     (17,860)  
Total other comprehensive loss     $ (9,688)     $ (17,889)  
Basic loss per common share (in dollars per share)     $ (1.18)     $ (2.18)  
Diluted loss per common share (in dollars per share)     $ (1.18)     $ (2.18)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended June 30, 2022 (unaudited)              
Compensation expense for issuance of stock options     $ 1,617     $ 3,091  
Net loss     (9,657)     (17,860)  
Consolidated Statement of Cash Flows for the six months ended June 30, 2022 (unaudited)              
Net loss     (9,657)     (17,860)  
Stock option compensation expense           3,091  
Adjustment              
Balance Sheet for June 30, 2022 (unaudited)              
Additional paid-in capital     1,299     1,299  
Accumulated deficit     (1,299)     (1,299)  
Consolidated Statement of Operations and Comprehensive Loss for the three months ended June 30, 2022 (unaudited)              
Research and development expenses     150     391  
Selling, general and administrative expenses     352     908  
Total operating expenses     502     1,299  
Operating loss     (502)     (1,299)  
Net loss     (502)     (1,299)  
Total other comprehensive loss     $ (502)     $ (1,299)  
Basic loss per common share (in dollars per share)     $ (0.06)     $ (0.16)  
Diluted loss per common share (in dollars per share)     $ (0.06)     $ (0.16)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended June 30, 2022 (unaudited)              
Compensation expense for issuance of stock options     $ 502     $ 1,299  
Net loss     (502)     (1,299)  
Consolidated Statement of Cash Flows for the six months ended June 30, 2022 (unaudited)              
Net loss     (502)     (1,299)  
Stock option compensation expense           1,299  
As revised              
Balance Sheet for June 30, 2022 (unaudited)              
Additional paid-in capital     437,221     437,221  
Accumulated deficit     (440,135)     (440,135)  
Consolidated Statement of Operations and Comprehensive Loss for the three months ended June 30, 2022 (unaudited)              
Research and development expenses     5,606     10,087  
Selling, general and administrative expenses     4,497     8,699  
Total operating expenses     10,103     18,786  
Operating loss     (9,486)     (17,826)  
Net loss     (10,159)     (19,159)  
Total other comprehensive loss     $ (10,190)     $ (19,188)  
Basic loss per common share (in dollars per share)     $ (1.24)     $ (2.34)  
Diluted loss per common share (in dollars per share)     $ (1.24)     $ (2.34)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended June 30, 2022 (unaudited)              
Compensation expense for issuance of stock options     $ 2,119     $ 4,390  
Net loss     (10,159)     (19,159)  
Consolidated Statement of Cash Flows for the six months ended June 30, 2022 (unaudited)              
Net loss     $ (10,159)     (19,159)  
Stock option compensation expense           $ 4,390